Password reminder
Interventional News
Contact the editor Visit Interventional News Twitter feed Visit Interventional News Facebook page

CREST set to report results early this year

Monday, 11 Jan 2010 13:46

Whilst one more time CREST (Carotid revascularization endarterectomy vs. stenting trial) presented only the lead-in data and postponed the long-awaited results to February or March 2010, a study showed great improvement with intensive medical therapy including statins. Thomas Brott told delegates that it is time to compare carotid intervention and best medical therapy again. The role of protection devices for stenting, which still lacks extensive data, was also debated

Three important questions on how to treat asymptomatic carotid stenosis patients were addressed by Thomas G Brott, neurologist, director for Research, Mayo Clinic, Jacksonville, USA. In the presentation titled ‘Where do we go from here with randomised trials of carotid artery stenting vs. carotid endarterectomy?’ Brott was challenged to answer if the field needs more trials with asymptomatic patients, better patient selection, and more trials with improved stents.

Brott started the presentation telling delegates that we need more trials in asymptomatic patients with a best medical treatment arm.

“We need information about asymptomatic patients. In part because of how many carotid interventions are done each year. There has been a drop in recent years, but we still have over 120,000 carotid interventions done each year in the United States and most of these procedures are done for asymptomatic patients,” he said.

More information is also needed, Brott said, because many physicians still wonder what to do about many patients. He exemplified with the case of a non-smoker with 70–80% stenosis, irregular plaque and 20% stenosis of the left internal carotid artery.

“What is your advice?” he questioned. He reminded delegates of the worldwide survey Management of Carotid Stenosis (N Engl J Med 2008;358:1617–1621) which showed that best medical treatment is favoured over any intervention in all continents. “Many of our colleagues prefer medical therapy over either stenting or surgery,” he said.

Brott said that, on the medical therapy side, the 2% annual medical risk of stroke that drove the difference between the surgical and medical arms in the ACAS (Asymptomatic carotid atherosclerosis study) and ACST (Asymptomatic carotid surgery trial) is probably too high today and could have something to do with the drop in carotid interventions seen in recent years.

He mentioned a range of improvements in medical therapy with statins, which decrease rates of stroke, myocardial infarction, decrease stroke severity, and impact on surrogate endpoints. In these improvements, Brott also included new hypertensive drugs – more effective and better tolerated (with the potential for greater compliance) – new antiplatelet drugs, potential for pharmacogenomic-guided choices, better treatments and glucose monitoring for diabetes, and ongoing drop in cigarette smoking. “In Europe cigarette smoking has dropped by 30%, and it is still dropping,” he said. “The medical side has made great advances. It is time to do the comparison between carotid intervention and best medical treatment in asymptomatic patients again.”

Do we need more trials with better patient selection? Although Brott told delegates that “yes, we do”, he added a “but”. “SPACE and CREST trials lead-in data showed relatively greater risk following stenting for those aged over 75 years. Probably about 25% of our patients in CREST are older than 75 years. How do we select them? We think studies have shown that severe tortuosity and heavy calcification are predictors of risk. Probably teasing out the variables in older patients, we will see that the endpoints are confounded by stroke from other causes, probably small vessels stroke, and decline in follow-up. Older patients develop or have already developed increasing morbidities. And we found in CREST that it is a real challenge to follow-up older patients, as their spouse becomes disabled or dies, transportation becomes more of a problem, and the effects of other diseases have their impact,” Brott said.

Do we need more trials with better technology for stenting (flow reversal and better stent systems)? “No, at least not randomised controlled trials,” Brott told delegates. “Randomised controlled trials are not the answer for everything, the arithmetic is prohibitive. In all trials the sample size increases as the effect size decreases. We already have good results from good technology. Proving the effects of ‘better’ technology would require more than 2,500 patients.”

Current status of the CREST trial

Wesley Moore, professor and chief emeritus, Division of Vascular Surgery, University of California Los Angeles Medical Center, reviewed the results from CREST, which is the largest trial to date that has randomised patients prospectively to either protected stent/angioplasty or carotid endarterectomy. This trial has several unique features, which Moore believes make it a superior study to those done in the past. One of the most important features is that the interventionalist has to be approved by a committee before they can perform carotid stenting.

This is to ensure that patients are treated by physicians with the appropriate background and experience. Thus, contrary to other trials, interventionalists were carefully selected and must be considered the top performers of carotid artery stenting.

This enables CREST to critically compare the outcome of the most talented interventionalists with the results of contemporary carotid endarterectomy.

Since the last patient was randomised in June 2008, Moore had intended to report one-year data, but due to administrative delays, the results are still in analysis, with expected publication in February or March, 2010. At the VEITHsymposium, Moore did report that the endpoint (death, stroke, or myocardial infarction) rate does statistically increase with age and bleeding complications.

Add New Comment

Most popular

Eluvia drug-eluting stent demonstrates 96.1% primary patency at 12 months
Monday, 28 Sep 2015
According to Boston Scientific, these results represent the highest 12-month primary patency reported for an interventional treatment of femoropopliteal artery lesions among comparable trials. Eluvia drug-eluting stent demonstrates 96.1% primary patency at 12 months

Perfusion angiography could help make essential decisions in critical limb ischaemia treatment
Monday, 12 Oct 2015
Jim Reekers, Amsterdam, The Netherlands, delivering the Josef Roesch honorary lecture at CIRSE 2015, urged delegates to look at new definitions for critical limb ischaemia and pointed to the ... Perfusion angiography could help make essential decisions in critical limb ischaemia treatment

Custom-designed vascular training model now available at events
Thursday, 05 Nov 2015
The ThinkRadial Vascular Training Model provides realistic simulation to several procedurally critical vascular destinations, while allowing the practitioner to “see” the way radial products perform ... Custom-designed vascular training model now available at events


Intra-arterial stem cell therapy “an emerging modality” for stroke patients
Wednesday, 18 Nov 2015
There have been five human studies using the intra-arterial route for delivery of a range of different bone marrow-derived stem cells. All have shown that this approach is feasible and safe, ... Intra-arterial stem cell therapy “an emerging modality” for stroke patients

Label drains to prevent errors and improve patient care
Wednesday, 18 Nov 2015
There are many gains to be had by instituting a drain labelling system within any hospital. It is surprising that this simple and useful practice has not been naturally adopted with the frequency of ... Label drains to prevent errors and improve patient care


Lindsay Machan
Thursday, 28 May 2015
“Focusing on maximising rewards has sidelined more ideas than it has helped individual inventors. S... Lindsay Machan

Gao-Jun Teng
Thursday, 11 Dec 2014
In the future, will interventional radiology be a subspecialty of radiology, or surgery? asks Gao-J... Gao-Jun Teng

Cardiac Rhythm News Vascular News Cardiovascular News Interventional News Spinal News NeuroNews
BIBA Medical BIBA MedTech Insights CX Symposium ilegx
Password Reminder

BIBA Medical, 526 Fulham Road, Fulham, London, SW6 5NR.
TEL: +44 (0)20 7736 8788 FAX: +44 (0)20 7736 8283 EMAIL: 
© BIBA Medical Ltd is a company registered in England and Wales with company number 2944429.
VAT registration number 730 6811 50.
Site Map | Terms and Conditions